CompletedPHASE1, PHASE2NCT02008877
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Studying Fibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Principal Investigator
- AeRang Kim, MD, PhD, C.S.L.PChildren's National Research Institute
- Intervention
- ganetespib(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2013 – 2018
Study locations (7)
- Sarcoma Oncology Center, Santa Monica, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Iowa, Iowa City, Iowa, United States
- National Cancer Institute, Bethesda, Maryland, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
Collaborators
Synta Pharmaceuticals Corp. · United States Department of Defense
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02008877 on ClinicalTrials.govOther trials for Fibrosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05566795DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Day One Biopharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03834961Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaChildren's Oncology Group